Background: Pancreatic carcinoma is one of the leading causes of cancer-related mortality. At the time of diagnosis, 30% of patients present with a locally advanced pancreatic carcinoma (LAPC). As circulating tumor cells (CTCs) count may be a surrogate of the cancer metastatic abilities, CTC detection rates and prognostic value were studied in a prospective cohort of LAPC patients.
introduction
Adenocarcinoma of the pancreas represents 10% of gastrointestinal cancers. In 2008, a worldwide annual incidence of more than 250 000 new cases was expected, with a poor survival [1] . Briefly, three different clinical settings may be depicted at diagnosis: (i) overt distant metastases requiring systemic chemotherapy; (ii) resectable tumor that can be treated by surgery followed by adjuvant chemotherapy and (iii) locally advanced pancreatic cancer (LAPC) which is nonresectable at diagnosis due to local invasion of major arterial axes (celiac trunk and/or superior mesenteric artery), but without detectable distant metastasis. Median overall survival (OS) is generally higher in LAPC (9-12 months) than in metastatic pancreatic cancer (6-8 months) [2] . It has been reported that 30% of LAPC patients died of locally destructive tumor progression, and 70% died of widespread metastatic disease [3] . The therapeutic options to manage LAPC are controversial. Schematically, the two main options are to focus either on the primary tumor mass with radiation therapy being the treatment backbone or on the systemic dissemination requiring full-dose systemic chemotherapy [4] . The use of induction chemotherapy followed by consolidation chemoradiation for patients without evidence of distant progression is a promising therapeutic strategy [5] , and the LAP 07 phase III international trial has been designed to prospectively assess its relevance. This randomized study assesses in patients whose cancer is controlled after 4 months of gemcitabine-based chemotherapy whether administration of chemoradiotherapy could increase OS versus continuation of chemotherapy alone.
Circulating tumor cells (CTCs) could represent a window into the metastatic process [6] , thus their study appears to be particularly relevant in the LAPC setting. As depicted above, LAPCs are characterized by the invasion of nearby vascular structures [7] : such vascular involvement may facilitate the hematogenic dissemination of primary tumor cells and release of CTCs. Moreover, CTC detection may be a valuable tool to monitor the metastatic process in these patients with no radiologically detectable metastases and may finally guide the physician's choice toward a systemic (chemotherapy-based) or local (radiotherapy-based) treatment. CTCs have not been studied yet in this specific clinical setting [8] . We report here the results of the prospective CTC detection in a subgroup of patients included in the LAP 07 trial (CirCe 07 ancillary study).
patients and methods

patients and treatments
The LAP 07 trial was an international randomized phase III trial intended to compare prospectively the sequential strategy presented above (chemotherapy followed by radiotherapy) versus chemotherapy alone in patients with non-resectable, non-metastatic LAPC. The main trial, identified as NCT00634725, and its ancillary study on CTC, CirCe 07, have been approved by the national ethics board. The main inclusion criteria were patients with de novo, histologically proven LAPC (stage III according to the 2002 UICC classification: T4: tumour involving celiac axis or superior mesenteric artery, any N, M0) and not considered for curative resection, performance status of 0-2, polynuclear neutrophils (PMNs) ≥1.5 × 10 9 /l, platelets ≥100 × 10 9 /l, hemoglobin ≥90 g/l, total bilirubin ≤1.5 × the upper limit of normal value (ULNV) unless recent biliary drainage (≤ 3 × ULNV), AST and ALT ≤ 2.5 × ULNV, alkaline phosphatase (ALP) ≤ 5 × ULNV, albumin ≥25 g/l and signed informed consent form. The serum marker CA 19.9 was measured at baseline in local laboratories.
Briefly, treatments were as follows: LAPC patients were initially randomly assigned to receive gemcitabine alone (arm A) or combined with erlotinib (arm B) for 4 months, with computed tomography (CT) scan evaluation at months 2 and 4. Patients with controlled disease (i.e. tumor response or stable disease) after this first chemotherapy phase at month 4 underwent a second randomization between administration of gemcitabine for two additional months (arm 1) or radiation therapy with concurrent capecitabine (arm 2). Patients allocated to receive erlotinib in the first phase continued erlotinib during the second phase (except during radiation therapy), and then as a maintenance treatment until progression. CT scans were carried out throughout the patient treatment every 2 months for detecting tumor progression.
circulating tumor cells detection
The CirCe 07 study included a subgroup of patients who participated in the LAP 07 trial and signed a specific informed consent. Two blood analyses were planned: the first (7.5 ml) at inclusion before any treatment and the second (7.5 ml), after 2 months of chemotherapy. Samples from 12 French centres were processed at Institut Curie.
The Cellsearch® technique (Veridex) has been reported previously [9] . Briefly, this procedure enriches Epcam-positive cells. CTCs are defined as nucleated cells lacking CD45 expression and expressing cytokeratin. Epidermal growth factor receptor-1 (EGFR) immunocytofluorescence staining (Veridex) was also assessed on detected CTCs.
data and statistical analysis
The main objective of the CirCe 07 study was to assess the detection rate of CTCs in LAPC patients. Secondary end points were to assess CTC correlation with baseline patients' characteristics, and patients' overall (OS) and progression-free (PFS) survivals. CTC detection was done whenever possible, and no attempt was made in this study to define target statistical power.
Baseline patient characteristics and outcomes were prospectively registered in electronic case report forms for all patients. CTC detection was blinded to patients and clinicians. OS and PFS were defined, respectively, as the time elapsed between the inclusion to the patient death and to tumor progression, as per RECIST 1.0 criteria. Differences between categorical variables were analyzed by a chi 2 test or Fisher's exact test.
Survival curves were plotted according to the Kaplan-Meier method. Statistical significance between survival curves was assessed using the logrank test. Multivariable analysis was done by the Cox proportional hazards model with prognostic factors with a P value of ≤0.10 in univariable analysis. For all analyses, a P value of ≤0 .05 was considered to be statistically significant. This report was written in accordance with the REporting of tumor MARKer studies guidelines.
results
CTC detection
The CirCe 07 study included 79 patients in 12 French centers from January 2009 to December 2011. Among them, 75 patients had a CTC count at baseline; 4 patients (5%) had one or more CTCs/7.5 ml detected at this time point. The second CTC count was carried out in 56 patients without tumor progression at first evaluation (i.e. 2 months). Among them, five (9%) patients had one or more CTCs/7.5 ml detected. CTC-positive patients at baseline and at 2 months were all different, leading to an overall detection rate of one or more CTCs/7.5 ml in 9 patients out of 79 [11%, 95% confidence interval = (4.1%-17.9%)]. Among them, CTC counts were mostly low: six patients had 1 CTC/7.5 ml, two patients had 2 CTCs/7.5 ml and one patient had a high count of 15 CTCs/7.5 ml. EGFR staining was considered as being positive on all CTCs detected but 2.
As a control, we used the same technique in four pancreatic cancer patients with overt metastases: two of them were CTC positive (8 and 44 CTCs/7.5 ml), most of these CTCs being considered as EGFR positive. These results were in line with previous studies in metastatic pancreatic cancer (as discussed beyond) and supported the continuation of the CirCe 07 study.
correlation with patients' characteristics
Baseline characteristics and correlation with CTC detection are shown in Table 1 . Due to the protocol inclusion criteria, patients were in rather good general condition, and baseline blood analysis abnormalities were limited. CTC positivity correlated only with poor tumor differentiation (P = 0.04). CTC detection was not associated with any of the randomization arms of the trial: arms A and B (first randomization) contained 4/38 and 5/41 CTC-positive patients, respectively; arms A1, A2, B1 and B2 (2nd randomization at 4 months for non-progressive patients) contained respectively 1/14, 1/13, 2/ 15 and 1/12 CTC-positive patients. These results allowed us to report these data independently of the main study results.
original articles Annals of Oncology correlation with outcome
In the Circe 07 study, at the time of analysis (June 2012), 61 patients (77%) had a tumor progression and 52 patients (66%) have died. The median PFS for this subgroup of 79 patients was 7 months (range: 1-22 months) and the median OS was 13 months (range 2-37 months).
Univariable analyses for PFS and OS are shown in Table 2 . For PFS, none of these characteristics, including CTC positivity, was prognostic, except poor differentiation that was significantly associated with shorter PFS. For OS, CTC positivity at baseline and at 2 months showed both a trend toward significance, with P values between 0.10 and 0.05. Overall CTC positivity (at baseline and/or at 2 months) was associated with a shorter OS (P = 0.01) ( Figure 1A) . The other adverse prognostic factors were baseline hemoglobin level under 110 g/l (P = 0.003) and elevated ALP (P = 0.03) ( Figure 1B and C) . In this study, which represents a small subset of the LAP07 trial, we were not able to show any significant interaction between CTC positivity (at baseline and/ or 2 months) or CTC-changes, treatment arms (A versus B, 1 versus 2) and survival (PFS or OS).
Finally, multivariable analyses were carried out on three models, including respectively CTC positivity at baseline, at 2 months and at baseline and/or 2 months (Table 3 ). These analyses suggested that CTC positivity at baseline (P = 0.04), CTC positivity at baseline and/or at 2 months (P = 0.01), and anemia (P < 0.01) were independent prognostic factors for OS. discussion LAPC is a special clinical presentation of pancreatic adenocarcinoma (30% of these cancers). Several treatment Adverse prognostic factors were tested in univariable analysis (log rank test). Significant P values are shown in bold. Annals of Oncology original articles modalities are debated, based on systemic and/or local treatment [4] . Some prognostic factors have been reported previously for LAPC patients, especially performance status [10] , weight loss [11] and anemia [10, 12] ; the impact of CA19.9 serum level is still controversial [13] . Actually, none of these prognostic factors are used in the routine management of LAPC patients.
Here, we report a CTC detection rate of 11% (4.1%-17.9%), using the low cut-off of one or more CTCs/7.5 ml of blood. This threshold is probably associated with a limited sensitivity, with several false-negative patients. So far, data on CTC detection with the CellSearch® system have been reported only in metastatic pancreatic cancer: CTC detection rates (≥1 CTC/ 7.5 ml) were higher, around 50% [9, [14] [15] [16] . Such difference was expected, as previously reported with other CTC detection techniques [17, 18] . This result was also in line with breast cancer studies, the CTC detection rate (≥1 CTC/7.5 ml) dropping from 70% in metastatic breast cancer [19, 20] to 20% in locally advanced breast cancer [21] . The association between CTC detection and poor differentiation of the tumor was not reported previously. Whether poorly differentiated pancreatic cancers more likely disseminate and induce CTC migration merits further studies. However, due to the limited number of patients in our cohort, the result of correlation or association studies should be considered with caution.
Beside CTC detection rate, a major finding of our results is that CTC positivity was a prognostic factor for OS in multivariable analysis in LAPC patients. This is the first study ever made in this specific clinical setting, and was therefore not statistically powered to derive further reliable and clinically relevant analyses such as prognostic models (e.g. nomograms), as recently reported in larger cohorts of metastatic breast cancer patients [22] . The impact of CTC positivity at two months appears less significant than at baseline, but the number of patients was lower, with a possible loss of statistical power. Other previous reports on CTC detection in pancreatic adenocarcinoma have been reviewed elsewhere [8] . Most of them were too small to draw any definitive conclusions.
Interestingly, although epithelial-mesenchymal transition has been repeatedly described in pancreatic adenocarcinomas [23] , our results suggest that the epithelial cells detected by CellSearch® do have a real impact on the course of the disease. In locally advanced breast cancer, CTC positivity with the same technique was also associated with distant metastasis-free original articles Annals of Oncology survival (DMFS) and OS [21] . In the current study, however, CTC positivity was associated with OS but not with PFS, which was defined as usual in the LAP 07 study, i.e. as the time to the appearance of a distant metastasis or to the growth of the primary tumor. As CTCs are generally believed to play a role in metastasis but not in the primary tumor growth, their prognostic value should have been ideally assessed on DMFSbut this specific parameter was not measured in the LAP 07 trial. Other possible explanations for a lack of CTCs impact on PFS are (i) the low statistical power of our study (ii) statistical fluctuations (e.g. a recent cohort did not report correlation between baseline CTC and PFS in metastatic breast cancer patients [24] , although this correlation was repeatedly demonstrated in other cohorts). Further studies are therefore required to investigate the impact of CTC on PFS in LAPC.
conclusion
The CirCe 07 study is the first prospective study ever reported on a large cohort of patients with LAPC and suggests that the cells that were retrieved have some prognostic impact. No recommendation can be made for the routine management of LAPC patients on the basis of this first study, and the association between CTC positivity and survival requires further independent validation. However, if our findings were confirmed in an independent cohort, CTCs may become useful for prognosis assessment or stratification, especially when a locoregional treatment such as radiation therapy is considered. funding This work was supported by Roche through a grant to GERCOR (Paris, France), which was the promoter of the LAP 07 trial and its ancillary study CirCe 07.
